Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Howard

Showing results (401-410 of 411) with videos related to

Pageof 42
Sort By:
Oncotarget|November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
The British Journal of Radiology|July 1, 1982
Seventh interim progress report of the british institute of radiology fractionation study of 3F/week versus 5F/week in radiotherapy of the laryngo-pharynxG Wiernik, T D Bates, R J Berry, et al.
American Journal of Human Genetics|March 21, 2000
Survey of the fragile X syndrome CGG repeat and the short-tandem-repeat and single-nucleotide-polymorphism haplotypes in an African American populationD C Crawford, C E Schwartz, K L Meadows, et al.
The Journal of Clinical Investigation|December 1, 2025
A protective and heterosubtypic antibody lineage targeting the influenza A virus neuraminidase active siteTy A Sornberger, Rachael M Wolters, Iuliia M Gilchuk, et al.
The British Journal of Radiology|October 1, 1972
Fifth progress report on the British Institute of Radiology fractionation trial of 3F-week or 5F-week treatment of larynx and pharynxG Wiernik, N M Bleehen, J Brindle, et al.
The British Journal of Radiology|August 1, 1970
Third progress report on the British Institute of Radiology fractionation study on 3F-week or 5F-week treatment of larynx and pharynxF Ellis, J Brindle, I F Churchill-Davidson, et al.
The British Journal of Radiology|March 1, 1971
Fourth Progress Report on the British Institute of Radiology fractionation study on 3F-week or 5F-week treatment of larynx and pharynxF Ellis, N Bleehen, J Brindle, et al.
American Journal of Medical Genetics|April 20, 1999
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary dataD J Allingham-Hawkins, R Babul-Hirji, D Chitayat, et al.
Biorxiv : the Preprint Server for Biology|February 3, 2025
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivityParker J Jamieson, Xiaoying Shen, Alexandra A Abu-Shmais, et al.
Journal of Virology|November 10, 2025
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivityParker J Jamieson, Xiaoying Shen, Alexandra A Abu-Shmais, et al.
Pageof 42

Showing results (401-410 of 411) with videos related to

Sort By:
Pageof 42
Oncotarget|November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumabGerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
The British Journal of Radiology|July 1, 1982
Seventh interim progress report of the british institute of radiology fractionation study of 3F/week versus 5F/week in radiotherapy of the laryngo-pharynxG Wiernik, T D Bates, R J Berry, et al.
American Journal of Human Genetics|March 21, 2000
Survey of the fragile X syndrome CGG repeat and the short-tandem-repeat and single-nucleotide-polymorphism haplotypes in an African American populationD C Crawford, C E Schwartz, K L Meadows, et al.
The Journal of Clinical Investigation|December 1, 2025
A protective and heterosubtypic antibody lineage targeting the influenza A virus neuraminidase active siteTy A Sornberger, Rachael M Wolters, Iuliia M Gilchuk, et al.
The British Journal of Radiology|October 1, 1972
Fifth progress report on the British Institute of Radiology fractionation trial of 3F-week or 5F-week treatment of larynx and pharynxG Wiernik, N M Bleehen, J Brindle, et al.
The British Journal of Radiology|August 1, 1970
Third progress report on the British Institute of Radiology fractionation study on 3F-week or 5F-week treatment of larynx and pharynxF Ellis, J Brindle, I F Churchill-Davidson, et al.
The British Journal of Radiology|March 1, 1971
Fourth Progress Report on the British Institute of Radiology fractionation study on 3F-week or 5F-week treatment of larynx and pharynxF Ellis, N Bleehen, J Brindle, et al.
American Journal of Medical Genetics|April 20, 1999
Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary dataD J Allingham-Hawkins, R Babul-Hirji, D Chitayat, et al.
Biorxiv : the Preprint Server for Biology|February 3, 2025
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivityParker J Jamieson, Xiaoying Shen, Alexandra A Abu-Shmais, et al.
Journal of Virology|November 10, 2025
Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivityParker J Jamieson, Xiaoying Shen, Alexandra A Abu-Shmais, et al.
Pageof 42